Aanchal Bhatia is the President and Chief Clinical Psychologist of Texas Medical Concierge, a global company based in India and Texas that provides medical concierge and telemedicine lounge services. These services allow clients to have access to the worlds leading doctors for any type of healthcare need.
Thank you for listening. We would appreciate your comments and reviews.
In This Episode, You’ll Learn
- About the company that caters to patients globally which provides medical concierge and telemedicine lounge services
- About how patients are able to access doctors of different specialization and their services depending on their healthcare needs
- About the types of things that they are focusing on
- About a campaign that they started advocating the widespread of respiratory disease
- About the major cause of death in India
- What kinds of diseases they have already treated
- About the after-care treatments they provide their patients
- About Aanchal’s recommendation or tips to patients who considers medical tourism to have their treatment done
- Texas Medical Concierge website
- Texas Medical Concierge Twitter
- Texas Medical Concierge Blog
- Breathe Easy India – a campaign Aanchal’s started advocating the widespread of respiratory disease
- Breathe Easy India Facebook Group
- Contact No.: +91 11 4619 4444
- Email: email@example.com
- Skype: texasmedicalconcierge
The Onwards Medical Breakthrough
A shot against heart attacks?
“Harvard Stem Cell Institute (HSCI) scientists collaborating with researchers at the University of Pennsylvania have developed a “genome-editing” approach for permanently reducing cholesterol levels in mice through a single injection, a development that could reduce the risk of heart attacks in humans by 40 to 90 percent.”
“For the first iteration of an experiment, this was pretty remarkable,” said Kiran Musunuru of HSCI, an assistant professor in Harvard’s Department of Stem Cell and Regenerative Biology (SCRB), and a cardiologist at Harvard-affiliated Brigham and Women’s Hospital. Musunuru stressed, however, that it could take a decade of concerted effort to get this new approach for fighting heart disease from the laboratory to phase I clinical trials in humans.
“The research was published online today byCirculation Research, a journal of the American Heart Association. Qiurong Ding, a postdoctoral fellow in Musunuru’s laboratory, is first author on the paper.”
You can learn more about this discovery at this link.